TITLE

Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity

AUTHOR(S)
Azad, Rajvardhan; Chandra, Parijat
PUB. DATE
July 2007
SOURCE
Indian Journal of Ophthalmology;Jul2007, Vol. 55 Issue 4, p319
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
25561932

 

Related Articles

  • Bevacizumab.  // Reactions Weekly;9/18/2010, Issue 1319, p11 

    The article describes the case of a male neonate who developed choroidal rupture after he received combined laser ablation treatment and intravitreal bevacizumab for aggressive posterior retinopathy of prematurity (ROP).

  • Retinal Detachment Despite Aggressive Management of Aggressive Posterior Retinopathy of Prematurity. Suk, Kevin K.; Berrocal, Audina M.; Murray, Timothy G.; Rich, Ryan; Major, James C.; Hess, Ditte; Johnson, Rose A. // Journal of Pediatric Ophthalmology & Strabismus;Nov/Dec2010, Vol. 47 Issue 6, pe1 

    Posterior retinopathy of prematurity (ROP) is unusual in its atypical features and its aggressive, rapidly progressive course. It is more difficult to recognize and to treat, with many of these eyes progressing to retinal detachment despite multiple treatments with laser or cryotherapy. The...

  • Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity: a case report. Sun, Hae; Choi, Kyung; Lee, Sung // Japanese Journal of Ophthalmology;Sep2012, Vol. 56 Issue 5, p476 

    Background: Intravitreal injection of bevacizumab in retinopathy of prematurity has shown satisfactory results without any systemic complications. However, increased fibrosis and tissue contraction are reported as adverse effects in some cases. Case: A premature girl, born at 29 weeks + 4 days...

  • No direct correlation with adverse events found for bevacizumab treatment of ROP.  // Ocular Surgery News;8/10/2015, Vol. 33 Issue 15, p16 

    The article discusses research which showed no adverse effects on the use of intravitreal bevacizumab in treating preterm infants of retinopathy of prematurity.

  • Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. Roohipoor, Ramak; Ghasemi, Hamed; Ghassemi, Fariba; Karkhaneh, Reza; Riazi-Esfahani, Mohammad; Nili-Ahmadabadi, Mehdi // Graefe's Archive of Clinical & Experimental Ophthalmology;Sep2011, Vol. 249 Issue 9, p1295 

    Background: To evaluate the results of intravitreal bevacizumab in terms of regression of retinopathy of prematurity (ROP). Methods: In this interventional case series, 12 eyes from January 2007 to December 2008 were included. Two groups of patients were considered. Group 1 included those ROP...

  • Intravitreal Bevacizumab Following Laser Therapy for Severe Retinopathy of Prematurity. Erol, Nazmiye; Gürsoy, Hüseyin; Sahin, Afsun; Basmak, Hikmet // Journal of Pediatric Ophthalmology & Strabismus;Jul/Aug2010, Vol. 47 Issue 4, pe1 

    Trial of intravitreal bevacizumab injection in 7 eyes of 4 infants with continued retinopathy of prematurity progression despite previous laser therapy was reported. Six of the eyes benefited from the therapy. Intravitreal bevacizumab injection may be an alternative therapy in progressive stage...

  • Intravitreal anti-VEGF yields significant benefit in treatment of stage 3+ ROP. Hasson, Matt // Ocular Surgery News;5/25/2011, Vol. 29 Issue 10, p30 

    The article discusses research on the effect of intravitreal bevacizumab treatment on patients with stage 3 acute retinopathy of prematurity, published in the 2011 issue of the "New England Journal of Medicine."

  • Physicians consider adopting intravitreal bevacizumab as routine treatment for ROP.  // Ocular Surgery News;5/25/2011, Vol. 29 Issue 10, p1 

    The article discusses a debate among U.S. physicians regarding the potential adoption of intravitreal bevacizumab as retinopathy of prematurity (ROP) treatment in 2011.

  • Less myopia seen after anti-VEGF treatment for ROP.  // Ocular Surgery News;7/10/2013, Vol. 31 Issue 13, p14 

    The article reports on a study in 2013 indicating that less myopia was seen with intravitreal bevacizumab injections than with laser or cryotherapy in infants with retinopathy of prematurity.

  • Paradoxical vascular–fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Zepeda-Romero, L. C.; Liera-Garcia, J. A.; Gutiérrez-Padilla, J. A.; Valtierra-Santiago, C. I.; Avila-Gómez, C. D. // Eye;Jan2010, Vol. 24 Issue 1, p202 

    A correction to the article "Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity" published in the 2010 issues of the journal is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics